Wells Fargo & Company E Ffector Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.37 - $0.69 $6 - $11	17 Added 5.72%	314 $0
Q3 2023 Nov 13, 2023	BUY	$0.49 - $0.88 $106 - $191	218 Added 275.95%	297 $0
Q2 2023 Aug 15, 2023	BUY	$0.35 - $1.39 $1 - $5	4 Added 5.33%	79 $0
Q1 2023 May 12, 2023	BUY	$0.35 - $0.67 $0 - $0	1 Added 1.35%	75 $0
Q4 2022 Feb 13, 2023	BUY	$0.38 - $0.66 $0 - $1	2 Added 2.78%	74 $0
Q3 2022 Nov 14, 2022	BUY	$0.08 - $1.41 $0 - $8	6 Added 9.09%	72 $0
Q2 2022 Aug 12, 2022	BUY	$1.3 - $3.84 $7 - $23	6 Added 10.0%	66 $0
Q1 2022 May 16, 2022	BUY	$3.85 - $8.2 $3 - $8	1 Added 1.69%	60 $0
Q4 2021 Feb 14, 2022	BUY	$5.71 - $13.15 $336 - $775	59 New	59 $0

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.